AU1189688A - Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states - Google Patents

Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states

Info

Publication number
AU1189688A
AU1189688A AU11896/88A AU1189688A AU1189688A AU 1189688 A AU1189688 A AU 1189688A AU 11896/88 A AU11896/88 A AU 11896/88A AU 1189688 A AU1189688 A AU 1189688A AU 1189688 A AU1189688 A AU 1189688A
Authority
AU
Australia
Prior art keywords
immunomodulator
utilization
preparation
drugs
acquired immunodeficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU11896/88A
Other versions
AU610561B2 (en
Inventor
Marc Yves Franck Clement Shelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1189688A publication Critical patent/AU1189688A/en
Application granted granted Critical
Publication of AU610561B2 publication Critical patent/AU610561B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utilization of morphine antagonists, such as Naltrexone, beta-endorphine 1-27, or their derivatives or analogs, in the preparation of an immunomodulator and/or antiviral drug for the treatment of acquired immunodeficiency states, particularly the infection by HIV.
AU11896/88A 1987-01-21 1988-01-21 Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states Ceased AU610561B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8700670 1987-01-21
FR8700670A FR2609632B1 (en) 1987-01-21 1987-01-21 NOVEL THERAPEUTIC APPLICATION OF 17- (CYCLOPROPYLMETHYL) -4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE AND PHARMACEUTICAL COMPOSITIONS FOR THIS USE

Publications (2)

Publication Number Publication Date
AU1189688A true AU1189688A (en) 1988-08-10
AU610561B2 AU610561B2 (en) 1991-05-23

Family

ID=9347124

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11896/88A Ceased AU610561B2 (en) 1987-01-21 1988-01-21 Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states

Country Status (9)

Country Link
EP (1) EP0278821B1 (en)
JP (1) JPH02502278A (en)
AT (1) ATE112488T1 (en)
AU (1) AU610561B2 (en)
DE (1) DE3851711D1 (en)
DK (1) DK524788A (en)
FR (1) FR2609632B1 (en)
OA (1) OA09124A (en)
WO (1) WO1988005297A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
US4877791A (en) * 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
RU2058553C1 (en) * 1994-03-18 1996-04-20 Иван Николаевич Головистиков Method of estimation of human immune status suppressive link
RU2056852C1 (en) * 1994-03-18 1996-03-27 Иван Николаевич Головистиков Agent for treatment of autoimmune diseases with suppressor immunodeficiency and a method of autoimmune diseases treatment
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
CN1652752A (en) * 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 Naltrexone hydrochloride compositions
PT2368553E (en) 2003-04-08 2015-03-03 Progenics Pharm Inc Pharmaceutical formulations containing methylnaltrexone
CN104248763A (en) 2005-03-07 2014-12-31 芝加哥大学 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
PL2565195T3 (en) 2007-03-29 2015-10-30 Wyeth Llc Peripheral opioid receptor and antagonists and uses thereof
CL2008000905A1 (en) 2007-03-29 2008-08-22 Progenics Pharm Inc COMPOUNDS DERIVED FROM MORFINA, ANTAGONISTS OF THE PERIPHERAL OPIOID RECEIVER; PREPARATION METHOD; PHARMACEUTICAL COMPOSITION; AND USE TO REDUCE THE EFFECTS OF ENDOGENA OPIOID ACTIVITY.
MX2009010550A (en) 2007-03-29 2009-12-14 Progenics Pharm Inc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
JP5358587B2 (en) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド Production and use of (R), (R) -2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases
US11285192B2 (en) 2019-03-13 2022-03-29 Adamis Pharmaceuticals Corporation Formulation including a combination of beta-endorphin and adrenocorticotropic hormone
KR20210137535A (en) * 2019-03-13 2021-11-17 아다미스 파마슈티칼스 코포레이션 Formulations comprising a combination of β-endorphin and adrenocorticotropic hormone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives

Also Published As

Publication number Publication date
DE3851711D1 (en) 1994-11-10
FR2609632A1 (en) 1988-07-22
OA09124A (en) 1991-10-31
ATE112488T1 (en) 1994-10-15
JPH02502278A (en) 1990-07-26
DK524788A (en) 1988-11-18
FR2609632B1 (en) 1991-03-29
DK524788D0 (en) 1988-09-21
EP0278821B1 (en) 1994-10-05
EP0278821A1 (en) 1988-08-17
WO1988005297A1 (en) 1988-07-28
AU610561B2 (en) 1991-05-23

Similar Documents

Publication Publication Date Title
AU1189688A (en) Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states
EP0509019A4 (en) Treatment of human retroviral infections with 2',3'-dideoxyinosine
AU591125B2 (en) Therapeutic nucleosides
NL970006I1 (en) Use of indolone derivatives for the manufacture of medicines to treat Parkinson's disease.
EP0373744A3 (en) Use of nalmefene or naltrexone in the treatment of autoimmune diseases
EP0379806A3 (en) Pyrimidines and their pharmaceutical acceptable salts, and their use as medicines
NL194728B (en) Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof.
DK602988D0 (en) NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL EFFECT AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS
ES2130114T3 (en) 5,11-DIHIDRO-6H-DIPIRIDO (3,2-B: 2 ', 3'-E) (1,4) DIAZEPINES AND ITS USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION.
EP0296573A3 (en) Novel nucleosides, their preparation and pharmaceutical novel nucleosides, their preparation and pharmaceutical compositions compositions
DE3873327D1 (en) PREPARATION OF MEDICINAL PRODUCTS FOR TREATING IMMUNITY.
DK541189A (en) USE OF NALMEFEN OR NALTREXON FOR THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF INTERSTITIAL CYSTITIS
AU1412088A (en) Therapeutic nucleosides
IE892654L (en) Therapeutic nucleosides
ES2108680T3 (en) USE OF THE N-N-BUTYL DERIVATIVE OF DESOXINOJIRIMICINA IN THE MANUFACTURE OF A MEDICINAL PRODUCT.
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AU5061090A (en) Aids therapy
WO1990005523A3 (en) Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
EP0235904A3 (en) Treatment of allergy with thymopentin
ES2066897T3 (en) 5,11-DIHYDRO-6H-PIRIDO (2,3-B) (1,4) BENZODIAZEPIN-6-ONAS AND -TIONAS AND THEIR USE IN THE PREVENTION OR TREATMENT OF AIDS.
HUT54300A (en) Process for producing medicaments suitable for antiviral treatment
HU9201316D0 (en) Process for the production of hiv treating medical preparation containing 9-amino-1,2,3,4 tetrahydro-acridine-1-ol derivatives as active agents
EP0419354A3 (en) Use of a complex of inosine with a n,n-dialkylamino-alkanol or one of its salts with a pharmacologically acceptable acid for the treatment of certain helmintic infections
FR2532547B1 (en) MEDICINAL PRODUCT BASED ON A QUINOLEIN CYCLOPENTA (B) DERIVATIVE AS A NEURO-MUSCULAR STIMULATOR